Share on StockTwits

Veracyte (NASDAQ:VCYT) is scheduled to issue its Q214 quarterly earnings data on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $9.36 million for the quarter.

Shares of Veracyte (NASDAQ:VCYT) opened at 14.50 on Tuesday. Veracyte has a 52 week low of $10.88 and a 52 week high of $19.00. The stock’s 50-day moving average is $15.15 and its 200-day moving average is $15.00. The company’s market cap is $307.0 million.

A number of analysts have recently weighed in on VCYT shares. Analysts at Janney Montgomery Scott initiated coverage on shares of Veracyte in a research note on Thursday, June 26th. They set a “buy” rating and a $25.00 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday, June 19th. They set an “overweight” rating and a $21.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $21.40.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.